title: Low-dose autologous in vitro opsonized erythrocytes. Radioimmune method and autologous opsonized erythrocytes for refractory autoimmune thrombocytopenic purpura in adults.
abstract: Adult patients with chronic autoimmune thrombocytopenic purpura (ATP), which proved refractory to various treatments, received a single dose of autologous in vitro opsonized erythrocytes with 100 micrograms of anti-D IgG. In 1983, 30 of these patients were treated with autologous erythrocytes that had been opsonized and labeled with 25 mCi (740 MBq) of technetium Tc 99m; this treatment was designated as the radioimmune method. Favorable responses were noted in 36% of patients so treated. In 1985, another group of 16 patients with refractory ATP received therapy with autologous opsonized erythrocytes (AOPE) and 55% of these patients showed favorable responses. Five (17%) of the patients treated using the radioimmune method attained a complete, long-term (greater than 35 months) remission of their ATP, and five (31%) of the patients treated using AOPE remained in complete remission over 270 days after cessation of therapy. Major complications were not seen. We concluded that the interaction of macrophages with low-dose AOPE is a successful therapeutic approach in ATP refractory to standard treatment.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D004351:Drug Resistance; D004912:Erythrocytes; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D008297:Male; D008875:Middle Aged; D009895:Opsonin Proteins; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D018029:Rho(D) Immune Globulin; D013667:Technetium / Q000627:therapeutic use*
chemical_list: D009895:Opsonin Proteins; D018029:Rho(D) Immune Globulin; D013667:Technetium